TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33826362
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (replacing vincristine in the OEPA/COPDac regimen); two cycles of AEPA and four cycles of CAPDac; residual node radiotherapy (25.5 Gy) for non-CR sites after chemotherapy
Study: 33826695
Drug: Yogurt consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt consumption (per 25 g/d)
Study: 33826695
Drug: High-fat milk
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat milk consumption (per 100 g/d)
Study: 33826695
Drug: Total nonfermented
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total nonfermented milk consumption (per 100 g/d)
Study: 33827114
Drug: Carfilzomib (20/36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (20/36 mg/m2), Lenalidomide (25 mg), Dexamethasone (20 mg) for 8 cycles followed by transplant and 1 year of lenalidomide maintenance (10 mg)
Study: 33827114
Drug: Carfilzomib (20/36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (20/36 mg/m2), Lenalidomide (25 mg), Dexamethasone (20 mg)
Study: 33827675
Drug: Glucose metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose metabolism in the right middle temporal gyrus (RMTG)
Study: 33827675
Drug: RMTG metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMTG metabolism
Study: 33828254
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg once daily plus Pembrolizumab 200 mg every 3 weeks
Study: 33829030
Drug: Enhanced High-Volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced High-Volume Preparation for Colonoscopy
Study: 33829030
Drug: Conventional Low-Volume
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Low-Volume Preparation for Colonoscopy
Study: 33829237
Drug: Fruit juice
Normalized name: Fruit Juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit juice intake at 1 year old (120 mL per day)
Study: 33829355
Drug: CKD-516 in
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-516 in combination with intravenous irinotecan (120 mg/m2), administered for five consecutive days followed by two days off.
Study: 33829783
Drug: AG-270, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-270, a first-in-class oral MAT2A inhibitor
Study: 33830058
Drug: treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual
Study: 33830168
Drug: CE-sparing technique
Normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE-sparing technique with intensity-modulated radiation therapy to 70 Gy at 2 Gy/fraction concurrent with standard chemotherapy with or without adjuvant durvalumab.
Study: 33830168
Drug: Standard chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemoradiation therapy (not explicitly detailed in the abstract).
Study: 33830168
Drug: CE-sparing technique
Normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE-sparing technique with intensity-modulated radiation therapy to 70 Gy.
Study: 33830407
Drug: ASP4132 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4132 5 mg
Study: 33830407
Drug: ASP4132 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4132 10 mg
Study: 33830407
Drug: ASP4132 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4132 7.5 mg
Study: 33830407
Drug: ASP4132 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4132 10 mg intermittent dosing (3 days on, 4 days off)
Study: 33830407
Drug: ASP4132 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4132 15 mg intermittent dosing (1 day on, 6 days off)
Study: 33830407
Drug: ASP4132 pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4132 pharmacokinetics
Study: 33831045
Drug: Low-dose beetroot
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose beetroot juice (BJ) supplementation (nitrate: 1.3 mmol/L)
Study: 33831045
Drug: High-dose beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose beetroot juice (BJ) supplementation (nitrate: 4.3 mmol/L)
Study: 33831045
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (BJ) supplementation (nitrate: 0.9 mmol/L)
Study: 33831732
Drug: Cemiplimab 200
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 200 mg every 2 weeks intravenously for up to 48 weeks
Study: 33831901
Drug: Automated administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated administration of ephedrine or phenylephrine via the ADIVA algorithm
Study: 33832543
Drug: Virtual family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual family-based treatment (vFBT)
Study: 33832946
Drug: Subcutaneous N-803
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous N-803 plus rituximab
Study: 33835229
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg once daily plus letrozole 2.5 mg once daily
Study: 33835265
Drug: SARS-CoV‑2 IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV‑2 IgG and IgM antibody tests using a high sensitivity/low specificity threshold
Study: 33835628
Drug: Floatation-Reduced Environmental
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Floatation-Reduced Environmental Stimulation Therapy (REST) for 90 minutes
Study: 33835866
Drug: Atezolizumab 1,200
Normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1,200 mg every 3 weeks until disease progression, unacceptable toxicity, loss of clinical benefit, or patient/physician decision
Study: 33835936
Drug: Email-based dialectical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Email-based dialectical behavioral therapy (DBT)
Study: 33835936
Drug: In-person dialectical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person dialectical behavioral therapy (DBT)
Study: 33836153
Drug: Serious treatment-related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serious treatment-related adverse events
Study: 33836153
Drug: Grade 3-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 3-4 treatment-related events
Study: 33836153
Drug: Common grade
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common grade 3-4 treatment-related events
Study: 33836153
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of pembrolizumab
Study: 33836262
Drug: No EVOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: No EVOO treatment
Study: 33836671
Drug: Weekly neurologist
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly neurologist consultations
Study: 33837055
Drug: Belapectin (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belapectin (2, 4, or 8 mg/kg IV 60 min before pembrolizumab) + pembrolizumab (200 mg IV every 3 weeks for five cycles)
Study: 33839074
Drug: ET-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-directed therapy (monotherapy)
Study: 33840050
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal
Study: 33840068
Drug: 3-month community
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month community intervention consisting of group education for type 2 diabetes knowledge, diet, exercise in combination with usual diabetes care
Study: 39538234
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly (AOM)
Study: 33840725
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication treatments
Study: 33840725
Drug: Bismuth-based quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based quadruple therapy
Study: 33840725
Drug: Longer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer treatment durations
Study: 33841012
Drug: Korea Red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korea Red Ginseng (KRG) 2,000 mg/day for 30 days
Study: 33842870
Drug: ASP0113 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP0113 (5 mg/mL, 1 mL, five injections)
Study: 33842908
Drug: UNI91104 (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: UNI91104 (inhaled and intranasal niclosamide)
Study: 33843258
Drug: Consensus decision-making
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consensus decision-making on continuation and regimen of preoperative antiplatelet therapy (APT)
Study: 33843599
Drug: Web-based dialectical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based dialectical behavior therapy (DBT) skills site with secure message coaching; no specific dosage or duration mentioned.
Study: 33844595
Drug: Pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (2 mg/kg or 200 mg every 3 weeks)
Study: 33844623
Drug: 9vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV vaccine (three doses: Day 1, Month 2, Month 6)
Study: 33845032
Drug: Renin-Angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-Angiotensin system inhibitors (RASi)
Study: 33845259
Drug: Post-transplantation bendamustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplantation bendamustine (PTB) at doses of 140 mg/m², 100 mg/m², and 70 mg/m²
Study: 33845893
Drug: Short-term (ST)
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term (ST) metformin withdrawal
Study: 33845893
Drug: Long-term (LT)
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term (LT) metformin withdrawal
Study: 33845905
Drug: Dalpiciclib 100
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib 100 mg, 125 mg, and 150 mg
Study: 33845905
Drug: Dalpiciclib 125
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib 125 mg and 150 mg cohorts
Study: 33845905
Drug: Dalpiciclib 150
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib 150 mg cohort
Study: 33846719
Drug: Intermittent preventative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP)
Study: 33846719
Drug: Malaria treatment
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria treatment after diagnosis alongside IPTp-SP
Study: 33847257
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum retinol (LSR) defined as serum retinol ≤20 µg/dl
Study: 33848093
Drug: Pediatric heat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric heat illness treatment
Study: 33848199
Drug: Treatment-related changes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related changes in left atrial structure, specific details not available.
Study: 33848258
Drug: Surgical therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy, balloon pulmonary angioplasty, and medical therapy (details collected at enrollment and follow-up)
Study: 33848258
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life surveys administered at enrollment and biannually
Study: 33849625
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment limitations
Study: 34741189
Drug: Treatment limitations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment limitations
Study: 33849625
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without treatment limitations
Study: 33849625
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with treatment limitations
Study: 33851477
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg p.o. b.i.d. for 14 days followed by imiquimod 5% cream topically to the most clinically active lesions 3 days a week for 28 days
Study: 33852104
Drug: LY3022855 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 100 mg QW with durvalumab 750 mg Q2W
Study: 33852104
Drug: LY3022855 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 50 or 100 mg QW with tremelimumab 75/225/750 mg Q4W
Study: 33852104
Drug: LY3022855 25/50/75/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 25/50/75/100 mg QW with durvalumab 750 mg Q2W
Study: 33852146
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (IL-2) treatment
Study: 33853614
Drug: EMG-triggered NMES
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG-triggered NMES in addition to robot therapy (hand group; n=10)
Study: 33854484
Drug: Semaglutide (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (once-weekly subcutaneously)
Study: 33854484
Drug: Semaglutide (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (once-daily orally)
Study: 33854572
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks to week 96
Study: 33854746
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two or three methods in treatment of CTEPH (specific methods not detailed in the abstract)
Study: 33856003
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (high-dose repletion therapy) for eight weeks
Study: 33856277
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg and escalating doses of lenalidomide on Days 1-7 with DA-EPOCH-R (Days 1-5) in 21-day cycles
Study: 33856599
Drug: PEG-BCT-100 at
Normalized name: PEG-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-BCT-100 at 2.7 mg/kg weekly intravenous
Study: 33857185
Drug: Inhaled sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sedation using volatile agents (Sevoflurane and Isoflurane) with the Anaesthetic Conserving Device (AnaConDa, Sedana Medical)
Study: 33857185
Drug: Inhaled sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sedation
Study: 33857917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of e-CBT and medication
Study: 33858040
Drug: Dasatinib combined
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib combined with multi-agent chemotherapy regimen
Study: 33858202
Drug: Chemotherapy (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (adjuvant or neoadjuvant)
Study: 33858486
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges (2/day for 90 days)
Study: 33858486
Drug: MTZ (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ (400 mg) and AMX (500 mg TID for 14 days)
Study: 33858486
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges and MTZ+AMX
Study: 33859147
Drug: Expedited partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited partner treatment (EPT)
Study: 33860280
Drug: Intra-operative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative infusion of [U-13C] glucose
Study: 33860864
Drug: Capacitive radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive radiofrequency (BTL-6000 TR-Therapy Pro®) applied for 10 min with epidermal temperature above 40°C
Study: 33860922
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole treatment for 8 weeks
Study: 33860922
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole treatment
Study: 33861204
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with pedometer and daily steps recorded in a diary
Study: 33861210
Drug: SPARC intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPARC intervention (Sex Workers Promoting Action, Risk Reduction, and Community Mobilization) drop-in center and mobile outreach program; services include harm reduction, reproductive health, sexual health care, medication-assisted treatment, legal aid, counseling, and distribution of harm reduction tools.
Study: 33861486
Drug: Trametinib 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 2.0 mg daily
Study: 33863803
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity measured by hyperinsulinemic euglycemic clamp
Study: 33863803
Drug: Insulin response
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin response in women who lost weight
Study: 33863856
Drug: Olorinab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olorinab (3 or 30 mg/kg) administered twice daily by oral gavage for 5 days starting 1 day before colitis induction
Study: 33863856
Drug: Olorinab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olorinab (1, 3, 10, or 30 mg/kg) administered twice daily by oral gavage for 5 days starting 24 days after colitis induction
Study: 33865150
Drug: Non-medical use
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-medical use (NMU) of drugs
Study: 33865150
Drug: Psychostimulant medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychostimulant medications
Study: 33865203
Drug: MEK inhibitor
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK inhibitor (MEKi)
Study: 33865434
Drug: Yimingjia adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimingjia adjunct therapy with desloratadine dry suspension
Study: 33865434
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with desloratadine dry suspension
Study: 33866531
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral sodium selenite (dosing regimens: 33 mg daily, 11 mg BID, 5.5 mg TID)
Study: 33866662
Drug: Medication history
Normalized name: histolyn CYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication history interview conducted by pharmacists
Study: 33866662
Drug: Patients taking
Normalized name: Lamictal Blue (For Patients Taking Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients taking more than 5 medications
Study: 33866662
Drug: Adverse drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse drug events (ADE) detected during the ED visit
Study: 33866662
Drug: Medication-related variables
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-related variables associated with increased hospital admission
Study: 33866938
Drug: Chemotherapy (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (single-agent paclitaxel or doxorubicin)
Study: 33867192
Drug: Lenvatinib (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (18 mg) plus everolimus (5 mg) orally once daily
Study: 33867481
Drug: Muscadine grape
Normalized name: Muscadine Grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscadine grape extract (MGE) capsules by mouth twice daily, 320 to 1600 mg total phenolics/d for 4 weeks
Study: 33868050
Drug: Imagery Rescripting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery Rescripting and Schema Therapy
Study: 33870151
Drug: TVB-2640 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVB-2640 (60 mg/m) as monotherapy
Study: 33871807
Drug: Mongersen 160
Normalized name: Mongersen
DrugBank: Mongersen (DB15019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mongersen 160 mg/day for 12 weeks
Study: 33871888
Drug: Double-positive for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-positive for LG3-A and donor-specific antibody (DSA)
Study: 33872131
Drug: Silver nanoparticles
Normalized name: Silver nanoparticles
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver nanoparticles (exact dosage and duration not specified)
Study: 33873093
Drug: Novel recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel recombinant five-antigen Staphylococcus aureus vaccine
Study: 33874975
Drug: Oral Ty21a
Normalized name: Salmonella typhi Ty21a live antigen 2000000000 UNT [Vivotif]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ty21a immunization
Study: 33875560
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy (BT; IV tissue plasminogen activator + EVT)